1. Home
  2. MBAI vs SNGX Comparison

MBAI vs SNGX Comparison

Compare MBAI & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.76

Market Cap

12.0M

Sector

N/A

ML Signal

N/A

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.48

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBAI
SNGX
Founded
2004
1987
Country
Israel
United States
Employees
85
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0M
11.2M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
MBAI
SNGX
Price
$1.76
$0.48
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
151.3K
1.7M
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.03
EPS
N/A
N/A
Revenue
N/A
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.29
$0.28
52 Week High
$3.92
$6.23

Technical Indicators

Market Signals
Indicator
MBAI
SNGX
Relative Strength Index (RSI) 51.31 46.56
Support Level $1.35 $0.28
Resistance Level $1.91 $1.48
Average True Range (ATR) 0.18 0.05
MACD 0.02 0.04
Stochastic Oscillator 45.70 98.26

Price Performance

Historical Comparison
MBAI
SNGX

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: